BACKGROUND:Patients receiving dialysis therapy for end-stage kidney failure have a high cardiovascular mortality that can only be partially explained by traditional risk factors. METHODS: This study was a post hoc analysis of a prospectively gathered data set from a randomized trial comparing outcomes in new haemodialysis patients treated withsevelamer or calcium-containing phosphate binders. Patients were followed from the time of enrollment until death or censor on 31 December 2005. Median follow-up was 3.6 years. Demographics, cardiovascular risk factors, laboratory data, medication use and severity of vascular calcification were available at baseline and over the first 18 months of dialysis. RESULTS: Baseline predictors of mortality included age, creatinine, heart rate, iPTH, C-reactive protein (CRP), coronary and aortic calcium scores and the presence of aortic valve calcification. Over the first 18 months, averages of diastolic blood pressure, BUN, creatinine, albumin, phosphorus, iPTH and CRP were all significantly different between survivors and non-survivors. A stepwise multivariable adjusted Cox regression model demonstrated that low BUN and albumin and high CRP along with the use of calcium-containing phosphate binders (rather than sevelamer) were the strongest predictors of mortality in patients new to haemodialysis. CONCLUSIONS: These findings suggest that non-traditional risk factors, such as inflammation and malnutrition measured during the first 18 months of dialysis, are important determinates of survival in new dialysis patients. In addition, the unique risk factor for dialysis patients, the use of calcium-containing phosphate binders, was associated with a higher mortality rate in patients new to dialysis.
RCT Entities:
BACKGROUND:Patients receiving dialysis therapy for end-stage kidney failure have a high cardiovascular mortality that can only be partially explained by traditional risk factors. METHODS: This study was a post hoc analysis of a prospectively gathered data set from a randomized trial comparing outcomes in new haemodialysis patients treated with sevelamer or calcium-containing phosphate binders. Patients were followed from the time of enrollment until death or censor on 31 December 2005. Median follow-up was 3.6 years. Demographics, cardiovascular risk factors, laboratory data, medication use and severity of vascular calcification were available at baseline and over the first 18 months of dialysis. RESULTS: Baseline predictors of mortality included age, creatinine, heart rate, iPTH, C-reactive protein (CRP), coronary and aortic calcium scores and the presence of aortic valve calcification. Over the first 18 months, averages of diastolic blood pressure, BUN, creatinine, albumin, phosphorus, iPTH and CRP were all significantly different between survivors and non-survivors. A stepwise multivariable adjusted Cox regression model demonstrated that low BUN and albumin and high CRP along with the use of calcium-containing phosphate binders (rather than sevelamer) were the strongest predictors of mortality in patients new to haemodialysis. CONCLUSIONS: These findings suggest that non-traditional risk factors, such as inflammation and malnutrition measured during the first 18 months of dialysis, are important determinates of survival in new dialysis patients. In addition, the unique risk factor for dialysis patients, the use of calcium-containing phosphate binders, was associated with a higher mortality rate in patients new to dialysis.
Authors: A Trombetti; C Stoermann; T Chevalley; B Van Rietbergen; F R Herrmann; P-Y Martin; R Rizzoli Journal: Osteoporos Int Date: 2012-10-26 Impact factor: 4.507
Authors: Juan Antonio Garcia-Bello; Rita A Gómez-Díaz; Alicia Contreras-Rodríguez; Juan O Talavera; Rafael Mondragón-González; Lorena Sanchez-Barbosa; Margarita Diaz-Flores; Adan Valladares-Salgado; Juan Manuel Gallardo; Alejandra Aguilar-Kitsu; Jesus Lagunas-Munoz; Niels H Wacher Journal: Pediatr Nephrol Date: 2014-02 Impact factor: 3.714
Authors: Andreas Pasch; Geoffrey A Block; Matthias Bachtler; Edward R Smith; Wilhelm Jahnen-Dechent; Spyridon Arampatzis; Glenn M Chertow; Patrick Parfrey; Xiaoye Ma; Juergen Floege Journal: Clin J Am Soc Nephrol Date: 2016-12-09 Impact factor: 8.237
Authors: Ruth Dubin; Mary Cushman; Aaron R Folsom; Linda F Fried; Walter Palmas; Carmen A Peralta; Christina Wassel; Michael G Shlipak Journal: BMC Nephrol Date: 2011-01-26 Impact factor: 2.388